Top

Published in:

Open Access 01-03-2012 | Review Article

Morphine metabolism, transport and brain disposition

Authors: Simona De Gregori, Manuela De Gregori, Guglielmina Nadia Ranzani, Massimo Allegri, Cristina Minella, Mario Regazzi

Published in: Metabolic Brain Disease | Issue 1/2012

Abstract

The chemical structures of morphine and its metabolites are closely related to the clinical effects of drugs (analgesia and side-effects) and to their capability to cross the Blood Brain Barrier (BBB). Morphine-6-glucuronide (M6G) and Morphine-3-glucuronide (M3G) are both highly hydrophilic, but only M6G can penetrate the BBB; accordingly, M6G is considered a more attractive analgesic than the parent drug and the M3G. Several hypotheses have been made to explain these differences. In this review we will discuss recent advances in the field, considering brain disposition of M6G, UDP-glucoronosyltransferases (UGT) involved in morphine metabolism, UGT interindividual variability and transport proteins.

Allegri M, De Gregori M, Niebel T et al (2010) Pharmacogenetics and postoperative pain: a new approach to improve acute pain management. Minerva Anestesiol 76(11):937–44PubMed

Bourasset F, Cisternino S, Temsamani J, Scherrmann JM (2003) Evidence for an active transport of morphine-6-β-D-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier. J Neurochem 86:1564–1567PubMedCrossRef

Bouw MR, Tunblad K, Hammarlund-Udenaes M (2001) Blood Brain Barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats – pharmacokinetic/pharmacodynamic modelling. Br J Pharmacol 134:1796–1804PubMedCrossRef

Campa D, Gioia A, Tomei A et al (2008) Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 83:559–566PubMedCrossRef

Carrupt PA, Testa B, Bechalany A et al (1991) Morphine 6-Glucuronide and Morphine 3-Glucuronide as molecular chameleons with unexpected lipophilicity. J Med Chem 34:1272–1275PubMedCrossRef

Christensen CB, Jǿrgensen LN (1987) Morphine-6-glucuronide has high affinity for the opioid receptors. Pharmacol Toxicol 60:75–76PubMedCrossRef

Coffman BL, King CD, Rios GR, Tephly TR (1998) The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 26(1):73–77

Coughtrie MW, Ask B, Rane A et al (1989) The enantioselective glucuronidation of morphine in rats and humans. Biochem Pharmacol 38:3273–3280PubMedCrossRef

Dagenais C, Rousselle C, Pollack GM, Scherrmann JM (2000) Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J Cereb Blood Flow Metab 20:381–386PubMedCrossRef

De Boer AG, van der Sandt ICJ, Gaillard PJ (2003) The role of drug transporters at the Blood-Brain-Barrier. Annu Rev Pharmacol Toxicol 43:629–656PubMedCrossRef

Di YM, Chan E, Wei MQ et al (2009) Prediction of deleterious non-synonymous single-nucleotide polymorphisms of human uridine diphosphate glucuronosyltransferase genes. AAPS J 11:469–480PubMedCrossRef

Fujita K, Ando Y, Yamamoto W et al (2010) Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. Cancer Chemother Pharmacol Jan 65(2):251–8CrossRef

Holthe M, Klepstad P, Zahlsen K et al (2002) Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1 *28 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol 58:353–356PubMedCrossRef

Innocenti F, Liu W, Fackenthal D, Ramírez J, Chen P, Ye X, Wu X, Zhang W, Mirkov S, Das S, Cook E Jr, Ratain MJ (2008) Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene. Pharmacogenet Genomics 18(8):683–97PubMedCrossRef

Johansson BB, Nordborg C, Westergren I (1990) Neuronal injury after transient opening of the blood-brain barrier: modifying factors. Johansson BB, Owman CG, Widner H. Pathophysiology of the blood-brain barrier. Amsterdam Elsevier 145–157

Lötsch J, Geisslinger G (2005) Are μ-opioid receptor polymorphisms important for clinical opioid therapy? TRENDS Mol Med 11(2):82–89PubMedCrossRef

Lötsch J, Tegeder I, Angst MS, Geisslinger G (2001) Antinociceptive effects of morphine-6-glucuronide in homozygous MDR1a P-glycoprotein knockout and in wildtype mice in the hotplate test. Life Sci 66:2393–2403CrossRef

Lötsch J, Schmidt R, Vetter G et al (2002a) Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein. J Neurochem 83:241–248PubMedCrossRef

Lötsch J, Zimmermann M, Darimont J (2002b) Does the A118G polymorphism at the μ-opioid receptor gene protect against morphine-6-glucuronide toxicity? Anesthesiology 97:814–819PubMedCrossRef

Minn A, Ghersi-Egea JF, Perrin R et al (1991) Drug metabolizing enzyme in the brain and cerebral microvessels. Brain Res Rev 16:65–82PubMedCrossRef

Murakami K, Kondo T, Chan PH (1997) Blood-brain barrier disruption: edema formation and apoprotic neuronal death following cold injury. Acta Neurochir Suppl (Wien) 70:234–236

Osborne R, Joel S, Trew D, Slevin M (1990) Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 47:12PubMedCrossRef

Polt R, Porreca F, Szabo LZ et al (1994) Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier. Proc Natl Acad Sci USA 91:7114–7118PubMedCrossRef

Romberg R, Olofsen E, Bijil H (2005) Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid induced respiratory depression despite reduced analgesic response. Anesthesiology 102:522–530PubMedCrossRef

Sai K, Itoda M, Saito Y et al (2006) Genetic variations and haplotype structures of the ABCB1 gene in a Japanese population: an expanded haplotype block covering the distal promoter region, andassociated ethnic differences. Ann Hum Genet 70:605–622PubMedCrossRef

Smith MT (2000) Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 27:524–528PubMedCrossRef

Stone A, Mackenzie P, Galetin A et al (2003) Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos 31:1086–1089PubMedCrossRef

Ulens C, Baker L, Ratka A et al (2001) Morphine-6beta-glucuronide and morphine-3-glucuronide, opioid receptor agonists with different potencies. Biochem Pharmacol 62(9):1273–1282PubMedCrossRef

Xie R, Bouw M, Hammarlund-Udenaes M (2000) Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecid-sensitive transport. Br J Pharmacol 131:1784–1792PubMedCrossRef

Yamada H, Ishii K, Ishii Y et al (2003) Formation of highly analgesic morphine-6-glucuronide following physiologic concentration of morphine in human brain. J Toxicol Sci 28:395–401PubMedCrossRef

Yoshimura H, Ida S, Oguri K, Tsukamoto H (1973) Biochemical basis for analgesic activity of morphine-6-glucuronide. Penetration of morphine-6-glucuronide in the brain of rats. Biochem Pharmacol 22:1423–1430PubMedCrossRef

Title: Morphine metabolism, transport and brain disposition
Authors: Simona De Gregori
Manuela De Gregori
Guglielmina Nadia Ranzani
Massimo Allegri
Cristina Minella
Mario Regazzi
Publication date: 01-03-2012
Publisher: Springer US
Published in: Metabolic Brain Disease / Issue 1/2012
Print ISSN: 0885-7490
Electronic ISSN: 1573-7365
DOI: https://doi.org/10.1007/s11011-011-9274-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Morphine metabolism, transport and brain disposition

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy

Myelin specific cells infiltrate MCAO lesions and exacerbate stroke severity

High level interleukin-6 in the medium of human pancreatic cancer cell culture suppresses production of neurotransmitters by PC12 cell line

Exploratory investigation on nitro- and phospho-proteome cerebellum changes in hyperammonemia and hepatic encephalopathy rat models

Glutamate carboxypeptidase II gene polymorphisms and neural tube defects in a high-risk Chinese population

Alcohol-induced psychotic disorder: brain perfusion and psychopathology—before and after anti-psychotic treatment